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Abstract
Objectives—We sought to evaluate risk factors for and molecular characteristics of community-
onset extended-spectrum cephalosporin-resistant (ESC-R) Enterobacteriaceae (EB) urinary tract 
infections (UTIs) in a United States health system.
Methods—A case-control study was conducted from 2010 through 2013. All patients presenting 
to the Emergency Department (ED) or outpatient practices with EB UTIs were included. Case 
patients had ESC-R EB UTIs. Control patients had ESC-susceptible EB UTIs and were matched 
1:1 on study year. Risk factors for ESC-R EB UTI were assessed using multivariable conditional 
logistic regression. A subset of case isolates was evaluated for extended-spectrum beta-lactamases 
(ESBLs).
Results—302 patients with community-onset EB UTI were included, of which 151 were cases. 
On multivariable analysis, risk factors for ESC-R EB UTI included: trimethoprim-
sulfamethoxazole use in the prior 6 months (odds ratio [OR], 2.40; 95% confidence interval [CI], 
1.22–4.70; P=0.011), older age (OR, 1.03; 95% CI, 1.01–1.04; P<0.001), diabetes (OR, 2.91; 95% 
CI, 1.32–6.41; P=0.008), and presentation to the ED (OR, 2.42; 95% CI, 1.31–4.46; P=0.005). The 
prevalence of ESBLs among 120 case isolates were: 52% CTX-M, 29% TEM, 20% OXA, and 
13% SHV. The prevalence of AmpC was 25%. Pulsed-field gel electrophoresis of the CTX-M E. 
coli isolates showed no distinct clusters.
Conclusions—We found that use of trimethoprim-sulfamethoxazole, older age, diabetes, and 
presentation to the ED were associated with community-onset ESC-R EB UTI. There was a high 
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prevalence of CTX-M among our community isolates. Further studies are needed to determine 
strategies to limit emergence of these organisms in the community.
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lactamase; Urinary tract infection; Community onset
INTRODUCTION
Antibiotic resistance continues to emerge and threaten our antibiotic arsenal (1). Of 
particular concern has been the emergence of bacteria resistant to extended-spectrum 
cephalosporins (ESC-R), particularly among Enterobacteriaceae (EB) species. Several 
studies have shown that ESC-R EB infections are associated with increased morbidity, 
mortality, and healthcare costs (2, 3). The primary mechanisms causing ESC-R among EB 
species include production of extended-spectrum beta-lactamases (ESBLs) or an AmpC 
beta-lactamase (4).
Urinary tract infections (UTIs) are the most common bacterial infection among adults in the 
community setting (5), and recent data have demonstrated marked increases in bacterial 
resistance to first line antibiotics used to treat UTIs in ambulatory settings (6). Resistance 
has been associated with increased microbiologic and clinical failure (7).
While ESC-R EB infections in health care settings have been highlighted as an important 
issue for many years, the emergence of ESC-R EB infections in the community has only 
recently been recognized. Since its initial description, the incidence of community-onset 
ESC-R EB infections has increased significantly (8–12). One study performed in 
Switzerland reported an increase in ESC-R EB prevalence among outpatients from 0.9% in 
2004 to 5.3% in 2011 (13).
Prior studies have sought to investigate risk factors for ESC-R EB infections in the 
community setting (9, 10, 12, 14–21). Identified risk factors have varied significantly across 
studies and have included: advanced age (10, 15, 16, 18, 20); diabetes mellitus (10, 22–24); 
prostatic disease (15); antibiotic use in the prior 3 months (10, 12, 15, 17, 18, 20, 21); and 
prior UTIs (15, 21). However, these studies have had significant limitations, including small 
sample sizes, focus on only bloodstream infections, which are generally less common in the 
community setting, and focus on only one organism. Further, only one prior study evaluating 
risk factors for community-onset UTI with an ESC-R organism was conducted in the United 
States (US); this study included only ESBL-producing Escherichia coli isolates, did not 
differentiate between true infection and colonization, and was performed nearly 10 years ago 
(20), raising concerns about generalizability to the present time given marked increases in 
resistance over the past decade (13). Given the limitations of the one prior study done in the 
US, and the marked differences in antibiotic use and expected ESC-R EB epidemiology 
across countries, the generalizability of the prior findings to the current US population is 
uncertain.
Anesi et al. Page 2













Characterizing the clinical and molecular epidemiology of ESC-R EB UTIs in the 
community setting is critical for identification of modifiable risk factors to curb further 
emergence of resistance, as well as for guiding appropriate empiric antibiotic therapy. 
Therefore, the objective of our study was to evaluate risk factors for community-onset ESC-
R EB UTIs among patients cared for in a large academic health system in the US. We also 
sought to evaluate the molecular epidemiology of ESC-R EB isolates causing community 
UTIs, including prevalence and types of ESBLs.
MATERIALS AND METHODS
Study design and setting
A case-control study was performed at two Emergency Departments (EDs) and a network of 
outpatient practices within the University of Pennsylvania Health System (UPHS), as 
follows: 1) the ED at the Hospital of the University of Pennsylvania (HUP), a 776-bed 
quaternary care medical center; 2) the ED at Penn Presbyterian Medical Center (PPMC), a 
331-bed academic medical center, and 3) the Practice-Based Research Network (PBRN), 
which is a collaboration among 246 primary care physicians at community and hospital-
based practices.
Study population
The initial source population was comprised of all patients presenting to an ED or an 
outpatient practice with a community-onset urine culture positive for EB between December 
21, 2010 and April 22, 2013. Eligible patients were identified through the HUP Clinical 
Microbiology Laboratory, which processes all cultures from HUP, PPMC, as well as >90% 
of urine cultures from PBRN practices. A patient was designated as having a community-
onset urine culture if it was obtained in the ED, outpatient practices, or within 72 hours of 
hospital admission from the ED or an outpatient clinic. Subsequently, only patients with a 
true urinary tract infection were included, as we sought to identify risk factors for ESC-R 
EB UTI rather than urinary colonization. A urine culture was considered indicative of an 
infection based on Centers for Disease Control and Prevention (CDC) definitions (25), with 
medical record review performed by an infectious diseases-trained physician (J.H.H.). 
Though these criteria were developed for surveillance purposes, they represent the only 
standardized definition of UTI and include the salient clinical features of UTI (25).
Case patients were defined as those with an EB UTI demonstrating resistance to an ESC 
(i.e., ceftriaxone or ceftazidime minimum inhibitory concentration [MIC] >1μg/mL) 
according to recent Clinical and Laboratory Standards Institute (CLSI) criteria (26). Control 
patients were those who had a UTI with ESC-susceptible EB during the study period (i.e., 
ceftriaxone and ceftazidime MICs ≤ 1 μg/mL). Control patients were randomly selected 
using a computerized random number generator from the source population and matched 
with case patients on study year in a 1:1 ratio.
Each patient was included as a subject only once. If an ESC-R EB was isolated on multiple 
occasions in the same patient, only the first episode of infection was considered. The study 
was approved by the institutional review board of the University of Pennsylvania.
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Data on case and control patients were abstracted from the UPHS electronic medical record 
system. Information was collected on demographics (e.g., age, gender, race), comorbidities 
(e.g., diabetes, malignancy, hemodialysis), urologic disorders (e.g., prior UTIs, urinary 
catheters, prostate disease within the last 6 months), recent skilled nursing facility or 
hospital stay, and culture location (ED versus outpatient practice).
All inpatient and outpatient antibiotic therapy in the preceding 6 months was documented. 
Antibiotics were classified for the purposes of analysis, as follows: penicillins (i.e. 
ampicillin, amoxicillin, nafcillin); extended-spectrum penicillins (amoxicillin-clavulanate, 
ampicillin-sulbactam, piperacillin-tazobactam); first-generation cephalosporins (i.e. 
cefadroxil, cefazolin, cephalexin); extended-spectrum cephalosporins (i.e. ceftriaxone, 
ceftazidime, cefpodoxime, cefepime); aminoglycosides; macrolides; fluoroquinolones; 
carbapenems; metronidazole; intravenous vancomycin; clindamycin; trimethoprim-
sulfamethoxazole; nitrofurantoin; and fosfomycin.
Susceptibility and molecular testing of Enterobacteriaceae isolates
Susceptibility testing of EB isolates was performed at the HUP Clinical Microbiology 
Laboratory. All isolates identified from study subjects were tested as part of routine care for 
susceptibility to other antibiotics using the semi-automated Vitek 2 identification and 
susceptibility system (bioMerieux, Inc., Durham, NC). Updated MIC breakpoints for 
ceftriaxone and ceftazidime were used without confirmatory ESBL testing according to 
CLSI guidelines (26).
One hundred and twenty (79.5%) of the 151 ESC-R EB isolates were available for further 
microbiologic testing. These isolates underwent confirmatory ESBL testing using the double 
disk method, using both cefotaxime and ceftazidime (26). Real-time polymerase chain 
reaction (PCR) using SYBR dye for qualitative detection of TEM, SHV, OXA-1, and CTX-
M type beta-lactamase genes, followed gel confirmation of the band sizes, were detected and 
grouped as previously described by the investigators was also performed (27). All strains 
with detectable TEM/SHV genes were further confirmed by Sanger sequencing. In addition, 
multiplex PCR for plasmid mediated AmpC enzymes was performed as previously described 
(28). Finally, the ESC-R EB isolates were screened for the presence of Klebsiella 
pneumoniae carbapenemase (KPC), using ertapenem susceptibility screening (29). Isolates 
with elevated ertapenem MICs were tested for the presence of KPC by PCR (29).
Molecular typing by pulsed field gel electrophoresis (PFGE)
The genetic relatedness of isolates was determined by molecular typing using PFGE as 
described previously (30). E. coli isolates that were positive for CTX-M ESBL were 
included in PFGE analysis. XbaI was used to prepare chromosomal digests (31). All results 
were analyzed using the Fingerprinting II Informatix Software version 3.0 (Bio-Rad 
Laboratories, Hercules, CA) and interpreted according to established criteria (32).
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Case and control patients were characterized by potential risk factors, including 
demographics, comorbidities, and prior antibiotic use. Continuous variables were compared 
using the Student t-test or Wilcoxon rank-sum test, and categorical variables were compared 
using the χ2 or Fisher exact test. Conditional bivariable logistic regression was used to 
examine the relationship between each potential risk factor and ESC-R EB UTI. An odds 
ratio (OR) and 95% confidence interval (CI) were calculated to evaluate the strength of any 
association. Multivariable conditional logistic regression was then performed, with variables 
from bivariable analyses with P values <0.20 considered for inclusion in the final 
multivariable model. Backward stepwise selection was performed for selection of variables 
in the final explanatory model, with results confirmed using likelihood ratio testing (33). All 
analyses were performed using STATA v.13.0 (StataCorp, College Station, Texas).
RESULTS
Study population
A total of 574 patients had a community-onset urine culture with EB during the study 
period. Of these, 258 were excluded as they did not represent true UTI. Among the 316 
community-onset UTIs, 151 were due to ESC-R EB and 165 were due to ESC-susceptible 
EB. One hundred fifty-one of the 165 control patients with community-onset UTI due to an 
ESC-susceptible EB were included and matched to the 151 case patients based on study 
year.
Among the entire study cohort of 302 patients, the median age was 56 years (interquartile 
range [IQR], 37–68), and 62 (21%) were men. With regard to racial classification, 143 
(47%) were categorized as “white.” Eighty-five (28%) patients presented to the ED, while 
217 (72%) presented to an outpatient practice. The most common pathogens isolated were 
Escherichia coli (76%), Klebsiella species (13%), and Enterobacter species (9%). Forty-
three (14%) patients required admission to a hospital (HUP or PPMC).
Risk factors for community-onset UTI due to ESC-R Enterobacteriaceae
On bivariable analysis (Table 1), several variables were noted to be significantly associated 
with community-onset UTI due to ESC-R EB, including older age (P<0.001), male gender 
(OR, 2.71; 95% CI, 1.47–5.01; P=0.001), presentation to the ED (OR, 2.39; 95% CI, 1.38–
4.14; P=0.002), surgery in the prior 6 months (OR, 1.79; 95% CI, 1.02–3.14; P=0.042), 
hospitalization in the prior 6 months (OR, 2.55; 95% CI, 1.52–4.28; P<0.001), diabetes 
mellitus (OR, 2.70; 95% CI, 1.31–5.58; P=0.007), malignancy (OR, 3.50; 95% CI, 1.73–
7.07; P<0.001), liver disease (OR, 3.67; 95% CI, 1.02–13.14; P=0.046), and receipt within 
the prior 6 months of a first-generation cephalosporin (OR, 2.42; 95% CI, 1.01–5.86; 
P=0.048), extended-spectrum cephalosporin (OR, 4.75; 95% CI, 1.62–13.96; P=0.005), 
trimethoprim-sulfamethoxazole (SXT) (OR, 2.06; 95% CI, 1.14–3.75; P=0.017), and 
intravenous vancomycin (OR, 10.0; 95% CI, 1.28–78.12; P=0.028).
On subsequent multivariable analysis (Table 2), receipt of SXT within the prior 6 months 
was significantly associated with ESC-R EB UTI (OR, 2.40; 95% CI, 1.22–4.70; P=0.011). 
Anesi et al. Page 5













Other independent risk factors associated with an ESC-R EB UTI were older age (OR, 1.03; 
95% CI, 1.01–1.04; P<0.001), diabetes mellitus (OR, 2.91; 95% CI, 1.32–6.41; P=0.008), 
and presentation to the ED (OR, 2.42; 95% CI, 1.31–4.46; P=0.005).
Susceptibility testing
Susceptibility testing was performed on all of the EB isolates. Among the 151 ESC-R 
isolates, the majority were also resistance to fluoroquinolones (67%) and SXT (57%). In 
addition, 20% were resistant to aminoglycosides, and 18% were resistant to nitrofurantoin 
(18%). Two percent were resistant to meropenem.
Microbiologic characterization
One hundred and twenty (79.5%) of the 151 ESC-R EB case isolates were available for 
further microbiologic testing. Seventy-five (62.5%) of these isolates were positive on double 
disk testing. Among the isolates that were negative on double disk testing, 31% had at least 
one ESBL present on PCR testing and 45% were positive for AmpC. Among the isolates 
that were positive on double disk testing, 4% did not have an ESBL present on follow-up 
PCR testing. The prevalence of ESBLs among the ESC-R isolates were as follows (Table 3): 
52% CTX-M, 29% TEM, 20% OXA, and 13% SHV. The number of ESBLs present in each 
ESC-R isolate varied: 28.3% had no ESBLs (specifically, no CTX-M, TEM, OXA, or SHV 
ESBLs), 34.2% had one ESBL, 34.2% had two ESBLs, 2.5% had three ESBLs, and 0.8% 
(one patient) had four ESBLs. Of the 28.3% ESC-R isolates that did not have an ESBL, the 
majority (n=19; 56%) was positive for AmpC.
Thirty (25%) of the 120 characterized isolates were positive for AmpC, and five (4%) 
isolates were positive for Klebsiella pneumoniae carbapenemase (KPC). Among the 120 
ESC-R EB isolates, there were 57 E. coli isolates that were positive for CTX-M. There were 
no distinct clusters among the 57 CTX-M E. coli isolates on PFGE analysis (Supplementary 
Figure 1). CTX-M groups among these 57 isolates were as follows: 34 (59.6%) were CTX-
M-1, 22 (38.6%) were CTX-M-4, and 1 (1.8%) was ungrouped.
DISCUSSION
In this case-control study, we found that recent use of SXT, older age, diabetes mellitus, and 
presentation to the ED (as opposed to an outpatient practice) were significant risk factors for 
community-onset ESC-R EB UTI in a US health system. Furthermore, we identified a high 
prevalence of CTX-M-producing EB causing UTIs in the community setting, with more than 
half of characterized ESC-R isolates positive for CTX-M. The results of our study are 
strengthened by a large sample size including patients who presented to two EDs and a large 
network of primary care practices in the US, focus on UTI which is the most common 
bacterial infection among adults in the community setting, and inclusion of all EB species 
that were resistant to extended-spectrum cephalosporins. This is only the second study to 
date to determine risk factors for community ESC-R EB UTI in the US and is the larger of 
the studies (20).
Our study showed that receipt of SXT during the prior 6 months was associated with the 
development of ESC-R EB UTI. Prior studies have found that antibiotic exposure is 
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associated with development of ESC-R EB UTIs, including receipt of penicillins, 
fluoroquinolones, second- and third-generation cephalosporins, or any beta-lactam antibiotic 
(10, 12, 15, 17, 18, 20). Only one prior study has shown a specific association between SXT 
and ESC-R EB infection (21). The association between SXT use and ESC-R EB UTI is 
likely due to SXT exerting broad selection pressure on gastrointestinal flora and promoting 
the development of resistance. This association is particularly significant because SXT is a 
commonly prescribed antibiotic in the community setting; given the high prevalence of 
ESBL EB organisms in the community, this suggests that SXT should be used cautiously in 
the community, and that agents with the narrowest possible spectrum, such as nitrofurantoin, 
should be used when appropriate. This finding also underscores the importance of effective 
antibiotic stewardship measures in the community setting. Further study is indicated to 
assess whether decreased use of SXT can decrease the incidence of community ESC-R EB 
UTIs.
Similar to previous studies (10, 15, 16, 18), we found that older age was also a significant 
risk factor for development of an ESC-R EB UTI in the community setting. UTIs are one of 
the most common infections in community-dwelling older adults due to a number of age-
related risk factors, including increased rates of neurogenic bladder, increased use of urinary 
catheters, benign prostatic hypertrophy in men, and vaginal atrophy and increased 
incontinence in women (34). Furthermore, older adults may be at higher risk for 
colonization and subsequent infection with antibiotic-resistant organisms, including ESC-R 
EB, as a result of chronic comorbidities and aging-related immunosenescence.
Comorbid diabetes mellitus was also associated with the development of community-onset 
ESC-R EB UTI in our study. The presence of diabetes mellitus is a well-described risk factor 
for infections due to ESC-R organisms (e.g., UTI, bacteremia) (10, 22–24). This elevated 
risk is likely related to the hyperglycemia-related impairment of immune response in 
diabetes mellitus as well as increased prescription of antibiotics for conditions such as 
asymptomatic bacteriuria (35).
The results of this study also showed that presentation to the ED (as opposed to an outpatient 
practice) was significantly associated with development of an ESC-R EB UTI in the 
community setting. Medically complex patients with greater healthcare and antibiotic 
exposures are more likely to present to the hospital ED, rather than an outpatient clinic, for 
presumed infection. It is also possible that patients with ESC-R EB UTIs were more 
symptomatic than those with an ESC-susceptible EB UTI and were thus more likely to 
present to the ED. Of note, in contrast to prior studies, our study did not show any 
significant association between recent hospitalization or stay in a long-term care facility and 
acquisition of an ESC-R EB UTI in the community (14, 19).
Finally, we found that there was a high prevalence (52%) of CTX-M ESBLs among the 
community ESC-R EB isolates that we evaluated, as well as a high prevalence of AmpC 
(25%). This is consistent with prior reports that have found an increasing prevalence of 
CTX-M in the community (9, 36–38). This high prevalence of CTX-M is concerning, given 
the association between CTX-M and multi-drug resistance, particularly to oral agents that 
are typically prescribed for community-onset UTIs. High rates of resistance to these oral 
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agents were confirmed in our study, with a resistance rate of 72% to both fluoroquinolones 
and SXT in CTX-M-positive isolates.
There are potential limitations of our study. Misclassification is a concern in case-control 
studies. However, the outcome of community ESC-R EB UTI was validated through medical 
record review by an infectious diseases-trained physician, rather than relying on diagnostic 
or billing codes. While we evaluated 80% of the 151 ESC-R EB isolates, lack of 
characterization of the entire group may have impacted estimates of ESBL prevalence and 
antibiotic susceptibility profiles. Finally, the present study was conducted in a single 
healthcare system, and the results may not be generalizable to other dissimilar institutions.
In conclusion, the results of our study demonstrated that recent use of SXT, older age, 
diabetes mellitus, and presentation to the ED were significant risk factors for the 
development of a community-onset UTI with an ESC-R EB organism in a US health system. 
Further studies are needed to evaluate the clinical impact of these ESC-R EB infections, as 
well as to determine optimal infection control strategies to limit the spread of these highly 
resistant and increasingly common organisms in the community.
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Table 1
Bivariable conditional logistic regression of risk factors for community-onset UTI due to extended-spectrum 
cephalosporin-resistant Enterobacteriaceae.
Variable Cases (n=151)a Controls (n=151)a OR (95% CI) P value
Age, median years (IQR) 60 (46–70) 49 (27–64) ---- <0.001
Male sex 43 (28) 19 (13) 2.71 (1.47–5.01) 0.001
Emergency Department 55 (36) 30 (20) 2.39 (1.38–4.14) 0.002
Surgery in prior 6 months 36 (24) 21 (14) 1.79 (1.02–3.14) 0.042
Hospitalization in prior 6 months 66 (44) 35 (23) 2.55 (1.52–4.28) <0.001
Non-white race 78 (52) 81 (54) 0.92 (0.59–1.45) 0.729
UTI in prior 6 months 65 (43) 57 (38) 1.22 (0.79–1.90) 0.372
Urinary catheter 14 (9) 8 (5) 1.86 (0.74–4.65) 0.187
Rehabilitation or SNF stay in prior 6 months 9 (6) 3 (2) 4.00 (0.85–18.84) 0.080
Prostate disease (if male) 20 (47) 6 (32) 1.00 (0.06–15.99) >0.999
Comorbidities
Diabetes mellitus 31 (21) 14 (9) 2.70 (1.31–5.58) 0.007
Malignancy 39 (26) 14 (9) 3.50 (1.73–7.07) <0.001
Hemodialysis 5 (3) 1 (1) 5.00 (0.58–42.80) 0.142
Solid organ transplant 13 (9) 6 (4) 2.17 (0.82–5.70) 0.117
Respiratory diseaseb 29 (19) 17 (11) 1.80 (0.96–3.38) 0.068
Liver diseasec 11 (7) 3 (2) 3.67 (1.02–13.14) 0.046
Medicationsd
Penicillins 8 (5) 4 (3) 2.33 (0.60–9.02) 0.220
Extended-spectrum penicillins 12 (8) 5 (3) 2.75 (0.88–8.64) 0.083
First-generation cephalosporins 18 (12) 8 (5) 2.42 (1.01–5.86) 0.048
Extended-spectrum cephalosporins 19 (13) 4 (3) 4.75 (1.62–13.96) 0.005
Fluoroquinolones 97 (64) 94 (62) 1.08 (0.69–1.69) 0.733
SXT 36 (24) 19 (13) 2.06 (1.14–3.75) 0.017
Nitrofurantoin 28 (19) 26 (17) 1.09 (0.62–1.91) 0.773
Fosfomycin 2 (1) 1 (1) 2.00 (0.18–22.06) 0.571
Vancomycin 10 (7) 1 (1) 10.0 (1.28–78.12) 0.028
Aminoglycosides 3 (2) 1 (1) 3.00 (0.31–28.84) 0.341
Macrolides 2 (1) 4 (3) 0.50 (0.09–2.73) 0.423
Clindamycin 4 (3) 5 (3) 0.80 (0.21–2.98) 0.739
Doxycycline 5 (3) 3 (2) 1.67 (0.40–6.97) 0.484
Carbapenems 5 (3) 1 (1) 5.00 (0.58–42.80) 0.142
Metronidazole 6 (4) 3 (2) 2.00 (0.50–7.97) 0.327
a
Data are presented as numbers (percentages) except where noted.
b
COPD or chronic bronchitis.

















Receipt in the prior 6 months.
Abbreviations: CI, confidence interval; IQR, interquartile range; OR, odds ratio; SNF, skilled nursing facility; SXT, trimethoprim-
sulfamethoxazole; UTI, urinary tract infection.
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Table 2
Multivariable conditional logistic regression model of risk factors for community-onset UTI due to extended-
spectrum cephalosporin-resistant Enterobacteriaceae.
Variable OR (95% CI) P value
Age 1.03 (1.01–1.04) <0.001
Presentation to ED 2.42 (1.31–4.46) 0.005
Diabetes mellitus 2.91 (1.32–6.41) 0.008
SXT receipt within prior 6 months 2.40 (1.22–4.70) 0.011
Abbreviations: CI, confidence interval; ED, Emergency Department; OR, odds ratio; SXT, trimethoprim-sulfamethoxazole; UTI, urinary tract 
infection.
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Table 3




CTX-M (CTX-M-1, CTX-M-4) 62 (52)
TEM (TEM-1, TEM-12) 35 (29)
OXA (OXA-1) 24 (20)
SHV (SHV 1, 11, 12, 28) 15 (13)
ampC (CIT, FOX, DHA) 30 (25)
KPC (KPC-1) 5 (4)
a
For 120 case isolates. The presence of ESBLs are not mutually exclusive (e.g., SHV and TEM can co-occur), so the total prevalence will be 
greater than 100%.
Abbreviations: ESBL, extended-spectrum beta-lactamase; KPC, Klebsiella pneumoniae carbapenemase.
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